Thale Jarvis of Crestone
joined us for World Anti-Microbial Resistance Congress USA 2015 to discuss 'novel drug discovery programs for emerging infectious diseases'.
In this presentation, learn about
CRS3123 for the treatment of
Clostridium difficile
infections.
Download the presentation to understand more about:
-
Crestone's mission
-
Clostridium difficile infection (CDI)
-
CRS3123: Key advantages vs. competition
...and
much
more!
Get your copy here!
To find out more about
how CRS3123 is competing in the gram positive market
, attend
World Anti-Microbial Resistance Congress USA 2016
held
September 8-9
in
Washington, DC
.